4.5 Review

Retinoic acid receptors and cancers

Journal

ANNUAL REVIEW OF NUTRITION
Volume 24, Issue -, Pages 201-221

Publisher

ANNUAL REVIEWS
DOI: 10.1146/annurev.nutr.24.012003.132407

Keywords

retinoic acid; retinoic acid receptors; retinoids; cancer

Funding

  1. NCI NIH HHS [CA82770, CA64945] Funding Source: Medline
  2. NIDCR NIH HHS [DE13139] Funding Source: Medline
  3. NIDDK NIH HHS [DK44517] Funding Source: Medline
  4. NATIONAL CANCER INSTITUTE [R01CA064945, R01CA082770] Funding Source: NIH RePORTER
  5. NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013139] Funding Source: NIH RePORTER
  6. NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044517] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Studies utilizing experimental animals, epidemiological approaches, cellular models, and clinical trials all provide evidence that retinoic: acid and some of its synthetic derivatives (retinoids) are useful pharmacological agents in cancer therapy and prevention. In this chapter, we first review the current knowledge of retinoic acid receptors (RARs) and their role in mediating the actions of retinoic acid. We then focus on a discussion of RARalpha and acute promyelocytic leukemia followed by a discussion of the role of RARs, in particular RARbeta expression, in other cancer types. Loss of normal RAR function in the presence of physiological levels of RA (either due to alterations in the protein structure or level of expression) is associated with a variety of different cancers. In some cases treatment with pharmacological doses of RA can be effective.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available